Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 59, Issue 12, Pages 5604-5621Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b01599
Keywords
-
Categories
Funding
- GlaxoSmithKline
- University of Strathclyde
Ask authors/readers for more resources
The autotaxin-lysophophatidic acid (ATX-LPA) signaling pathway is implicated in a variety of human disease states including angiogenesis, autoimmune diseases, cancer, fibrotic diseases, inflammation, neurodegeneration, and neuropathic pain, among others. As a result, ATX-LPA has become of significant interest within both the industrial and the academic communities. This review aims to provide a concise overview of the development of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available